Project: Reactive Oxygen Species (ROS) Activators to Treat the Rare disease Guillain-Barré Syndrome (GBS)
Acronym | rosaGBS (Reference Number: 10082) |
Duration | 01/04/2016 - 01/10/2018 |
Project Topic | We will establish a novel therapeutic treatment of the orphan paralysis condition Guillain-Barré Syndrome (GBS), to enable orphan drug designation, clinical development and out-licensing to a Pharma partner. The project will also validate new In Vitro tests notably on human pluripotent stem cell-derived neural tissues to analyse neurotoxicity and optimise methodology to improve the bioavailability of compounds with difficult administration properties by medicinal chemistry and formulation. |
Network | Eurostars 2 |
Call | Eurostars Cut-Off 4 |
Project partner
Number | Name | Role | Country |
---|---|---|---|
22811 | RedGlead Discovery AB | Partner | Sweden |
22812 | Neurix SA | Partner | Switzerland |
22813 | ProNoxis AB | Coordinator | Sweden |